A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN 74809 in participants with primary sclerosing cholangitis (PSC) and suspected liver fibrosis (INTEGRIS-PSC).

  • Roberts, Stuart (Primary Chief Investigator (PCI))
  • Adams, Leon Anton (Chief Investigator (CI))
  • George, Jacob (Chief Investigator (CI))
  • Strasser, Simone Irene (Chief Investigator (CI))
  • Thompson, Alexander J.V. (Chief Investigator (CI))
  • Lynch, Kate D. (Chief Investigator (CI))

Project: Research

Project Details

Project Description

Protcol number PLN-74809-PSC-203
Effective start/end date1/10/201/11/23


  • Gastroenterology
  • Primary Sclerosing Cholangitis
  • Liver fibrosis
  • Clinical trial